ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO1075

Assessing Baseline Medication Use in CKD: An Analysis of the SHARP-ER Study

Session Information

Category: CKD (Non-Dialysis)

  • 1901 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention


  • Jun, Min, The George Institute for Global Health, UNSW Sydney, Newtown, New South Wales, Australia
  • Sukkar, Louisa, The George Institute for Global Health, Sydney, New South Wales, Australia
  • Jardine, Meg J., The George Institute for Global Health, UNSW, Newtown, New South Wales, Australia
  • Talbot, Ben, George Institute, Erskineville, New South Wales, Australia
  • Cass, Alan, Menzies School of Health Research, Darwin, Northern Territory, Australia
  • Landray, Martin J., University of Oxford, Oxford, United Kingdom
  • Reith, Christina A., CTSU, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom
  • Walker, Robert J., University of Otago, Dunedin, New Zealand
  • Gallagher, Martin P., The George Institute for Global Health, UNSW Sydney, Newtown, New South Wales, Australia

Group or Team Name

  • SHARP-ER Study Collaborators

Medication use of patients with CKD in Australia is accepted as high, but systematic, national data has not been available. The Pharmaceutical Benefits Scheme (PBS), a national program providing medication subsidies in Australia, offers a novel means of medication use pattern assessment in CKD based on routinely collected data. We assessed baseline medication use in CKD patients of the SHARP-ER study using PBS data.


Australian participants from the SHARP-ER study, a 5-year post-trial (2010-2015) extended follow-up of SHARP participants known to be alive at the end of the trial (study of cholesterol-lowering in CKD) in Australia, New Zealand and Malaysia, were linked to the PBS. Prescription medication dispensation in the year prior to SHARP-ER baseline, defined as the first study visit which occurred 1.5-2 years following the final SHARP visit, were obtained. We examined medication use (receipt of ≥1 prescription) from any of the following medication groups: cardioprotective (blood pressure-lowering, lipid-lowering, glucose-lowering, anticoagulant, antiplatelet, anaemia treatment), anti-infective, immunosuppressant, proton pump inhibitor (PPI) treatment and others.


Of 304 participants, 86 (28.3%) were on maintenance dialysis at baseline. Overall, there were 11,272 unique prescriptions dispensed in the year prior to baseline which included those for cardioprotective (58.4%), anti-infective (9.6%), immunosuppressive (7.6%), PPI (12.6%) treatment and others (11.6%). On average, patients were prescribed 6 different medications (IQR:4-8). The distributions of medication use across the medication groups in the 304 participants were: 92.8%, 68.4%. 25.3%, 53.3% and 54.3%, respectively. The proportion of patients receiving ≥3 medication groups was significantly higher among those on dialysis (76.7% vs. 64.7%;p=0.04) compared with non-dialysis CKD patients.


PBS data in patients with moderate-to-severe CKD suggests a high medication burden primarily directed at cardiovascular risk mitigation. Further longitudinal assessments of cardioprotective and anti-infective medication use according to patient characteristics are needed.


  • Government Support - Non-U.S.